Form 8-K - Current report:
SEC Accession No. 0001213900-26-062155
Filing Date
2026-05-28
Accepted
2026-05-28 16:31:45
Documents
13
Period of Report
2026-05-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0291692-8k_polaryx.htm   iXBRL 8-K 38862
2 FORM OF SECURITIES PURCHASE AGREEMENT BY AND BETWEEN THE COMPANY AND PURCHASERS ea029169201ex10-1.htm EX-10.1 36405
3 PRESS RELEASE DATED MAY 28, 2026 ea029169201ex99-1.htm EX-99.1 14173
  Complete submission text file 0001213900-26-062155.txt   275068

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE plyx-20260527.xsd EX-101.SCH 3011
5 XBRL LABEL FILE plyx-20260527_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE plyx-20260527_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0291692-8k_polaryx_htm.xml XML 3455
Mailing Address SOUTH TOWER, 140 E RIDGEWOOD AVENUE SUITE 415 PARAMUS NJ 07652
Business Address 140 EAST RIDGEWOOD AVENUE SUITE 415, SOUTH TOWER PARAMUS NJ 07652 201-940-7236
Polaryx Therapeutics, Inc. (Filer) CIK: 0002075320 (see all company filings)

EIN.: 000000000 | State of Incorp.: WY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-43080 | Film No.: 261036782
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)